Predictabiosciences
Cambridge, US · 1 known investors
Predicta develops a molecular insights platform for blood cancer care that generates genomic and immune profiling from blood samples to guide treatment decisions and monitor disease evolution. The platform combines whole-genome sequencing of circulating tumor cells with single-cell immune profiling to help clinicians and researchers understand disease biology and track treatment response in hematological malignancies.
BiotechDigital HealthMedical Devices